Recombinant human insulin-like growth factor I: effects in normal subjects and implications for use in patients.
Guler
H P
HP
Department of Medicine, University Hospital, Zurich, Switzerland.
Wettstein
K
K
Schurr
W
W
Zapf
J
J
Froesch
E R
ER
D000328:Adult; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002096:C-Peptide / Q000097:blood / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D013006:Growth Hormone / Q000097:blood* / Q000187:drug effects; D006801:Humans; D007263:Infusions, Parenteral; D007328:Insulin / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012016:Reference Values; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D011994:Recombinant Proteins; D014280:Triglycerides; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D002784:Cholesterol